Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Revenue (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Revenue for 6 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue changed N/A to $7.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.4 million, a 53.44% increase, with the full-year FY2025 number at $15.4 million, up 53.44% from a year prior.
  • Revenue was $7.0 million for Q4 2025 at Relay Therapeutics, up from $677000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $25.2 million in Q3 2023 to a low of -$1000.0 in Q4 2023.
  • A 5-year average of $3.5 million and a median of $616500.0 in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 13420.0% in 2021, then tumbled 100.4% in 2023.
  • Relay Therapeutics' Revenue stood at $567000.0 in 2021, then tumbled by 55.38% to $253000.0 in 2022, then crashed by 100.4% to -$1000.0 in 2023, then soared by 1000800.0% to $10.0 million in 2024, then crashed by 30.06% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Revenue are $7.0 million (Q4 2025), $677000.0 (Q2 2025), and $7.7 million (Q1 2025).